ClinicalTrials.gg
CompletedNCT06573424Updated May 1, 2025

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

An observational study in Colon Cancer and Immunotherapy, sponsored by fan li. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by fan li · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
124
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Enrollment
36th of 47
124 · median 400
Started
2024
with 26 others
Observational
47 of 211
16 open now
Registered
152nd of 211
by date

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 36th largest by enrollment of the 47 observational ones that give a count, is one of 27 that started in 2024, is one of 47 observational ones, and was the 152nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab

Read the detailed description

This was a multicenter retrospective cohort study to compare the efficacy of tyrosine kinase inhibitor(TKI) combined with immune checkpoint inhibitors(ICIs) versus tyrosine kinase inhibitor alone in the treatment of advanced MSS colorectal cancer. Patients with MSS CRC who have been confirmed by pathology and have relapsed or failed multiline therapy were included in the study. Patients who had received tirellizumab plus anlotinib were considered the combination group, and those treated with anlotinib were classified as the monotherapy group. The efficacy and safety of the two regimens were compared. At the same time, Whole-exome sequencing and transcriptome sequencing were performed on the patients in the response and non-response groups of the combination group to reveal the characteristics of their microenvironment and search for biomarkers related to response.

03

Conditions studied

  • Colon Cancer
  • Immunotherapy

Browse trials for

Keywords

  • Immunotherapy
  • Multi-omics analysis
  • tirellizumab
  • anlotinib
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with advanced MSS type colorectal cancer between November 2020 and May 2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-70 years old
  • Patients with mss colorectal cancer who have been confirmed by pathology and have or failed multiline therapy
  • Patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg, once every 3 weeks)
  • the presence of at least one measurable target lesion according to the (RECIST) version 1.1

Exclusion criteria

Exclusion Criteria:

  • Patients with other malignant tumors
  • Prior treatment with antirotinib, , anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibody or drug that specifically targets T cell co-stimulation or checkpoint pathways
  • Follow-up was less than 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
124 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • combination group

    Patients who have been treated with anlotinib + tislelizumab

    Combination Product: Tislelizumab+anlotinib

  • control group

    Patients who have been treated with anlotinib monotherapy

    Drug: anlotinib

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

    Time frame: 36 months

Secondary outcomes

  1. OS

    the time from the beginning of treatmentto death of any cause

    Time frame: 36 months

  2. Multiomic molecular characterization of the response to combination immunotherapy

    Including WES and RNA-seq analysis. using WES(Whole-exome sequencing) to analyse the differences in the mutational profiles between responders and non-responders. RNA-seq was used to reveal pathways and TME feature associated with the response to the combination therapy

    Time frame: 36 months

07

Study locations

1 site
  • Daping Hospital, Third Military Medical University
    Chongqing, 400042, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jul 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 27, 2024
StartActual
May 1, 2024
Primary completionActual
Jul 1, 2024
CompletionActual
Oct 31, 2024
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573424
Lead sponsor
fan li
Responsible party
fan li (Prof, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University) — Sponsor-investigator
First posted
Aug 27, 2024
Start date
May 1, 2024
Primary completion
Jul 1, 2024
Completion
Oct 31, 2024
Last update
May 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion